PP_1170x120_10-25-21

oral FDA-approved therapies used to treat relapsing forms of multiple sclerosis (MS

Study affirms oral disease-modifying therapies are well tolerated with high medication adherence rates

Study affirms oral disease-modifying therapies are well tolerated with high medication adherence rates

ORLANDO, Fla. — A recent study of patients receiving oral FDA-approved therapies used to treat relapsing forms of multiple sclerosis (MS) revealed high tolerance, low rates of adverse drug events, and similar medication adherence rates across all study medications. The retrospective study was conducted by AllianceRx Walgreens Prime, a leading specialty and home delivery pharmacy, in conjunction with Duquesne